The were co-infected with HIV; 116 patients (76%) had detectable HCV RNA, with genotypes 1a (68%) and 4a (32%); 21 (17%) had clinically significant fibrosis (≥F2) and 6 (5%) had cirrhosis (F4). None were offered HCV treatment. Chronic hepatitis C among PWID enrolled in the OST centre in Dar-es-Salaam is frequent, but its continuum of care is insufficient; integration of HCV diagnosis and treatment should form a part of OST intervention in PWID in Tanzania. This study aimed to assess the severity of liver disease and cascade of care for HCV-infected PWID registered at one of the largest opioid substitution therapy (OST) clinic in Dar-es-Salaam, Tanzania, East Africa. We also determined the proportion of significant liver fibrosis or cirrhosis using liver stiffness measurement (LSM), as measured by ultrasound-based transient elastography, and assessed the diagnostic accuracy of APRI, Fib-4 and GPR using LSM as a reference test.
| INTRODUC TI ON
An estimated 71 million people are chronically infected with the hepatitis C virus (HCV) worldwide and each year between 400 000 and 700 000 deaths are attributable to this virus. 1, 2 The World Health Organisation (WHO) has recently called for HCV elimination. 3 In its 2016-2021 global hepatitis plan, the WHO defined ambitious strategies to achieve 90% reduction in new HCV cases and 65% decrease in HCV-related mortality by 2030. 3 Intravenous drug use is a major driver of HCV spread worldwide and the WHO has clearly identified people who inject drugs (PWID) as a key population to target for HCV screening, prevention and care. 4 It is estimated that 10 million of 16 million PWID across the world are positive for HCV antibody. Africa. 6 Hence, East Africa is a point of geographical significance and is widely considered the gateway for African narco-trafficking, with 90% of the imported heroin destined for distribution to both continental and global sites. In 2013, it was estimated that 22 tons of heroin passed through East Africa annually, with 2.5 tons being consumed locally. 7 Costing as little as USD$1 per "hit," it is estimated that 30 000-45 000 people who inject heroin in Tanzania.
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Data on the burden of HCV among PWID in SSA are scarce. A study in Sénégal reported a high prevalence of HCV infection in drug users, but did not analyse the severity of the liver disease and furthermore, the drug users were mainly noninjectors. 9 In East Africa, there have been a handful of descriptive studies, restricted to assessing the seroprevalence of HCV infection, ranging from 28%-53%
in Tanzania to 42% in Kenya. [10] [11] [12] Lack of access to HCV nucleic acid testing (NAT), is a major obstacle to identifying chronically-infected individuals encountered across resource-limited settings. This study aimed to assess the severity of liver disease and cascade of care for HCV-infected PWID registered at one of the largest opioid substitution therapy (OST) clinic in Dar-es-Salaam, Tanzania, East Africa. We also determined the proportion of significant liver fibrosis or cirrhosis using liver stiffness measurement (LSM), as measured by ultrasound-based transient elastography, and assessed the diagnostic accuracy of APRI, Fib-4 and GPR using LSM as a reference test. 
| ME THODS

| Study population
| Ethical consideration
The study received clearance from both Muhumibili University for 
| HCV genotyping
Samples were analysed at Henri-Mondor Hospital (Creteil, France)
for genotyping and HCV RNA confirmation. HCV genotypes and subtypes were determined by means of the reference method that is sequencing of the nonstructural 5B region of the HCV genome, followed by phylogenetic analysis, as previously described.
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| Statistical analysis
The characteristics of the study participants were presented by me- 
| RE SULTS
| Hepatitis C cascade of care
A total of 1350 PWID were registered at the OST clinic at MNH since its Figure 1 summarizes the cascade of care for HCV in this population.
| General characteristics
During the study timeframe, 153 consecutive PWID (median age Table 1 .
| Severity of liver fibrosis
The median noninvasive scores of liver fibrosis are indicated in 
| Performance of biochemical scores using LSM as a reference
The performance of each biochemical score for correctly categorizing significant liver fibrosis or cirrhosis, using LSM as a reference, is summarized in Table 2 . With the AUROC being below 0.60, the overall performance of these tests for the diagnosis of fibrosis and cirrhosis was not acceptable. To diagnose of clinically significant fibrosis (≥F2), the low cut-off APRI (<0.5) had the best sensitivity (73%), while a cut-off value at 2 had a poor sensitivity for the diagnosis of cirrhosis, but a very good specificity (95%). However, its utility is hampered by the fact that more than half of the resulting scores presided in the "grey zone," between the different cut-off values.
| D ISCUSS I ON
The diagnosis of HCV among PWID in Tanzania accessing the largest OST clinic is limited to serology testing on registration. Our study other report of genotyping performed in PWID in East Africa (Kenya). 21 In addition, we found 17% of patients with significant liver fibrosis according to LSM including 5% with cirrhosis. At the time of writing, there has been no access to direct-acting antiviral (DAA) interferon-free therapy for PWID in Tanzania.
To our knowledge, this is the first study to provide a comprehensive screening and assessment cascade of care for HCV in PWID in Africa. There have been two previous studies estimating HCV seroprevalence among PWID in Tanzania, reporting a prevalence of 28% and 53%, respectively. 10, 12 Both previous studies also confer our finding of a heavily predominant male population. 10, 12 Although this may truly reflect that injecting drug use is more commonly practiced among men, the difference is likely to per test), 25 with a fully automated assay available on the Abbott ARCHITECT ® platform. It has been recently validated in African resource-limited settings and has been proposed as a one-step diagnostic alternative to conventional screening in such an environment. [26] [27] [28] An additional challenge to testing PWID is poor venous access. To overcome this issue, Grebley and colleagues have demonstrated good performance of using blood drawn from a finger-prick on the GeneXpert ® HCV RNA assay, which also has relatively low cost (at US$17 per test). 29 Alternatively, we have recently developed a diagnostic algorithm for resource-constraint PWID settings, which incorporates HCVcAg in serum and dry blood spots (DBS). however, their utility in resource-limited settings has been poorly documented. To our best knowledge, our study is the first to report TA B L E 2 Diagnostic accuracy of APRI, Fib-4 and GPR using LSM as a reference in patients with chronic hepatitis C the burden of liver fibrosis among PWID in SSA, with 17% of patients having clinically significant fibrosis (≥F2), including 5% with cirrhosis according to LSM. This is lower than the rate reported in European, Australian and American cohorts of PWID with chronic HCV, where the proportion of subjects with significant fibrosis is often over 30%. [30] [31] [32] limited by the lack of statistical power due to the relatively small number of patients with F2-F4 fibrosis, it is important to note that serum biochemistry and platelet count can be influenced by alcohol consumption and infections (particularly HIV), which are both welldocumented issues in the PWID community. 34 The latter is an issue which has also been identified in a recent validation of APRI in HCV/ HIV co-infection in Cambodia.
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Mathematical models have shown that scaling-up harm reduction services, through OST and NSPs, in combination with DAA therapy will help achieving HCV elimination in PWID. 36 In populations with escalating incidence of PWID, a failure to integrate harm reduction strategies into any proposed healthcare intervention can have a significant impact on HCV transmission, as evidenced by the recent "opioid crisis" in parts of North America. 37, 38 In Tanzania, there are an estimated 50 000 PWID, with only 3000 engaging in a local OST programme. Furthermore, the WHO has endorsed the use of generic treatments, having recently pre-qualified generic Sofosbuvir and adding various combinations to the WHO essential medications list.
42
It is important to recognize the role of local policymakers in taking responsibility for the implementation of a sustained test-andtreat policy. The commitment to a national action plan in Tanzania ensures that there is an agreed personnel and financial strategy in place to achieve the prescribed objectives. In 2013, only 63% of WHO member states (including Tanzania) had not submitted a national hepatitis strategy. 43 Although Tanzania is considered a pioneer in Africa for its OST programme, it is dependent on funding through the President's emergency plan for AIDS relief (PEPFAR).
Recent changes to the local healthcare agenda threaten to deprioritize the OST programme, while the well-publicised reduction of international foreign aid also poses a real risk to the existence of this once-acclaimed initiative.
Our study has some limitations: first, it reflects HCV-related 
